Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 427-437

  Berner, Reinhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antibiotic resistance; Epidemiology; GBS; Group B Streptococcus; Immune response; Innate immunity; Intrapartum antibiotic prophylaxis; Maternal colonization; Meningitis; Neonatal sepsis; Streptococcus agalactiae; Vaccine

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CD14 ANTIGEN; CEFAZOLIN; CHEMOTAXIN; CLINDAMYCIN; CYTOKINE; ERYTHROMYCIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMININ; LINCOSAMIDE; LIPOPOLYSACCHARIDE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOCOCCUS VACCINE; STREPTOGRAMIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL COLONIZATION; BLOOD CULTURE; CEREBRAL PALSY; DRUG ERUPTION; HEARING IMPAIRMENT; HUMAN; IMMUNE RESPONSE; LABOR; MENTAL DEFICIENCY; MORTALITY; NONHUMAN; PATHOGENESIS; PERINATAL INFECTION; PERINATAL MORBIDITY; PERINATAL MORTALITY; PREMATURITY; REVIEW; SEIZURE; SEPSIS; STILLBIRTH; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 2942612456     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.427     Document Type: Review

References (83)

1. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J. Pediatr. 82, 724-729 (1973).
2. Barton LL, Feigin RD, Lins R. Group B β-hemolytic streptococcal meningitis in infants. J. Pediatr. 82, 719-723 (1973).
3. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J. Pediatr. 82, 707-718 (1973).
4. Heath PT, Balfour G, Weisner AM et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363, 292-294 (2004).
5. Zaleznik DF, Rench MA, Hillier S et al. Invasive disease due to group B streptococcus in pregnant women and neonates from diverse populations. Clin. Infect. Dis. 30, 276-281 (2000).
6. Baltimore RS, Huie SM, Meek JI et al. Early onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 108, 1094-1098 (2001).
7. Schrag SJ, Zywicki S, Farley MM et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 342, 15-20 (2000).
8. Schuchat A, Zywicki SS, Dinsmoor MJ et al. Risk factors and opportunities for prevention of early onset neonatal sepsis. A multicenter case-control study. Pediatrics 105, 21-26 (2000).
9. Berner R. Group B streptococci in pregnancy and infancy. Curr. Opin. Infect. Dis. 15, 307-313 (2002).
10. Davies HD, Raj S, Adair C et al. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr. Infect. Dis. J. 20, 879-884 (2001).
11. Manning SD, Pearlman ME, Tallman P et al. Frequency of antibiotic resistance among group B streptococcus isolated from healthy college students. Clin. Infect. Dis. 33, e17-e139 (2001).
12. Schuchat A. Epidemiology of Group B streptococcal disease in the United States: shifting paradigms. Clin. Microbiol. Rev. 11, 497-513 (1998).
13. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 33, 556-561 (2001).
14. Davies HD, Adair C, McGeer A et al. Antibodies to capsular polysaccharides of group B streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J. Infect. Dis. 184, 285-291 (2001).
15. Berner R, Bender A, Rensing C, Forster J, Brandis M. Low prevalence of the immunoglobulin A binding β-antigen of the C protein among Streptococcus agalactiae isolates causing neonatal sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 18, 545-550 (1999).
16. Rubens CE, Wessels MR, Heggen LM, Kasper DL. Transposon mutagenesis of Type III group B streptococcus: correlation of capsule expression with virulence. Proc. Natl Acad. Sci. USA 84, 7208-7212 (1987).
17. Musser JM, Mattingly SJ, Quentin R et al. Identification of a high-virulence clone of Type III Streptococcus agalactiae (group B streptococcus) causing invasive neonatal disease. Proc. Natl Acad. Sci. USA 86, 4731-4735 (1989).
18. Bohnsack JF, Takahashi S, Detrick SR et al. Phylogenetic classification of serotype III group B streptococci on the basis of hylB gene analysis and DNA sequences specific to restriction digest pattern Type III. J. Infect. Dis. 183, 1694-1697 (2001).
19. Bohnsack JF, Whiting AA, Bradford RD et al. Long-range mapping of the Streptococcus agalactiae phylogenetic lineage restriction digest pattern Type III reveals clustering of virulence genes. Infect. Immun. 70, 134-139 (2002).
20. Bidet P, Brahimi N, Chalas C, Aujard Y, Bingen E. Molecular characterization of serotype III group B streptococcus isolates causing neonatal meningitis. J. Infect. Dis. 188, 1132-1137 (2003).
21. Berner R, Csorba J, Brandis M. Different cytokine expression in cordblood mononuclear cells (CBMNC) after stimulation with neonatal sepsis or colonizing strains of Streptococcus agalactiae. Pediatr. Res. 49, 691-697 (2001).
22. Adderson EE, Takahashi S, Wang Y, Armstrong J, Miller DV, Bohnsack JF. Subtractive hybridization identifies a novel predicted protein mediating epithelial cell invasion by virulent serotype III group B streptococcus agalactiae. Infect. Immun. 71, 6857-6863 (2003).
23. Tettelin H, Masignanin V, Cieslewicz MJ et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl Acad. Sci. USA 99, 12391-12396 (2002).
24. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol. Microbiol. 45, 1499-1513 (2002).
25. Von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R. A serotype V clone is predominant among erythromycin resistant Streptococcus agalactiae isolates in a south-western region of Germany. J. Clin. Microbiol. 41, 2166-2169 (2003).
26. Franken C, Haase G, Brandt C et al. Horizontal gene transfer and host specificity of β-haemolytic streptococci: the role of a putative composite transposon containing scpB and Imb. Mol. Microbiol. 41, 925-935 (2001).
27. Doran SK, Liu GY, Nizet V. Group B streptococcal β-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. J. Clin. Invest. 112, 736-744 (2003).
28. Harris TO, Shelver DW, Bohnsack JF, Rubens CE. A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis and cleavage of human fibrinogen. J. Clin. Invest. 111, 61-70 (2003).
29. Jones AL, Neeeham RHV, Clancy A, Knoll KM, Rubens CE. Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance. Mol. Microbiol. 47, 247-256 (2003).
30. Jarva H, Hellwage J, Sakaari Jokiranta T, Lehtinen MJ, Zipfel PF, Meri S. The group B streptococcal-β and pneumococcal-Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J. Immunol. 172, 3111-3118 (2004).
31. Doran KS, Chang JCW, Benoit VM, Eckmann L, Nizet V. Group B streptococcal β-hemolysin/cytolysin promotes invasion of human lung epithelial cells and release of interleukin-8. J. Infect. Dis. 185, 196-203 (2002).
32. Berner R, Niemeyer CM, Leititis JU et al. Plasma levels and gene-expression of G-CSF, TNF-α, IL-1β, IL-6, IL-8 and sICAM-1 in neonatal early onset sepsis. Pediatr. Res. 44, 469-477 (1998).
33. Berner R, Fuerll B, Stelter F, Droese J, Mueller HP, Schuett C. Elevated plasma levels of lipopolysaccharide binding protein (LBP) and soluble CD14 in neonatal early onset sepsis. Clin. Diagn. Lab. Immunol. 9, 440-445 (2002).
34. Teti G, Mancuso G, Tomasello F. Cytokine appearance and effects of antitumor necrosis factor antibodies in a neonatal rat model of group B streptococcal infection. Infect. Immun. 61, 227-232 (1993).
35. Joyner JL, Augustine NH, Taylor KA, La Pine RT, Hill HR. Effects of Group B streptococci on cord and adult mononuclear cell interleukin 12 and interferon-γ mRNA accumulation and protein secretion. J. Infect. Dis. 182, 974-977 (2000).
36. Cusumano V, Mancuso G, Genovese F et al. Role of γ-interferon in neonatal mouse model of group B streptococcal disease. Infect. Immun. 64, 2941-2944 (1996).
37. Mancuso G, Cusumano V, Genovese F et al. Role of interleukin-12 in experimental neonatal sepsis caused by group B streprococci. Infect. Immun. 65, 3731-3725 (1997).
38. Cusumano V, Midiri A, Cusumano VV et al. Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect. Immun. 72, 295-300 (2004).
39. Medvedev AE, Flo T, Ingalls RR et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-κB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J. Immunol. 160, 4535-4542 (1998).
40. Berner R, Welter P, Brandis M. Cytokine expression of cord and adult blood mononuclear cells in response to Streptococcus agalactiae. Pediatr. Res. 51, 304-309 (2002).
41. Henneke P, Takeuchi O, Malley R et al. Cellular activation, phagocytosis and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J. Immunol. 169, 3970-3977 (2002).
42. Cuzzola M, Mancuso G, Beninati C et al. Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products. Infect. Immun. 68, 994-998 (2000).
43. Henneke P, Takeuchi O, van Strijp JA et al. Novel engagement of CD14 and multiple Toll-like receptors by group B streptococci. J. Immunol. 167, 7069-7076 (2001).
44. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. Morbid. Mortal. Wkly. Rep. 51 (RR-11), 1-24 (2002).
45. Votava M, Tejkalová M, Drábková M et al. Use of GBS media for rapid detection of group B streptococci in vaginal and rectal swabs from women in labor. Eur. J. Clin. Microbiol. Infect. Dis. 20, 120-122 (2001).
46. Park CH, Vandel NM, Ruprai DK et al. Detection of group B streptococcal colonization in pregnant women using direct latex agglutination testing of selective broth. J. Clin. Microbiol. 39, 408-409 (2001).
47. Podbielski A, Blankenstein P. Lütticken R. Molecular charaterization of the cfb gene encoding group B streptococcal CAMP-factor. Med. Microbiol. Immunol. 183, 239-256 (1994).
48. Bergeron MG, Ke D, Menard C et al. Rapid detection of group B streptococci in pregnant women at delivery. N. Engl. J. Med. 343, 175-179 (2000).
49. Schrag SJ, Zell ER, Lynfield R et al. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. N. Engl. J. Med. 347, 233-239 (2002).
50. Davies RL, Hasselquist MB, Cardenas V et al. Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization. Am. J. Obstet. Gynecol. 184, 603-610 (2001).
51. Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am. J. Obstet. Gynecol. 179, 879-883 (1998).
52. Byington CL, Rittichier KK, Bassett KE et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 111, 964-968 (2003).
53. Stoll BJ, Hansen N, Fanaroff AA et al. Changes in pathogens causing early onset sepsis in very-low-birth-weight infants. N. Engl. J. Med. 347, 240-247 (2002).
54. Hyde TB, Hilger TM, Reingold A et al. Trends in incidence and antimicrobial resistance of early onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics 110, 690-695 (2002).
55. Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatr. Infect. Dis. J. 18, 524-528 (1999).
56. Chen KT, Tuomala RE, Cohen AP et al. No increase in rates of early onset neonatal sepsis by non-group B streptococcus or ampicillin-resistant organisms. Am. J. Obstet. Gynecol. 185, 854-858 (2001).
57. Jakobi P, Goldstick O, Sujov P, Itskovitz-Eldor J. New CDC guidelines for prevention of perinatal group B streptococcal disease. Lancet 361, 351 (2003).
58. Bedford-Russell AR, Breathnach A, Sender P. Confirmed group B streptococcus infections: the tip of the iceberg. Arch. Dis. Child. Fetal Neonatal Ed. 84, F140 (2001).
59. Luck S, Torny M, d'Agapeyeff K et al. Estimated early onset group B streptococcal neonatal disease. Lancet 361, 1953-1954 (2003).
60. Regan JA, Klebanoff MA, Nugent RP et al. Colonization with group B streptococci in pregnany and adverse outcome. Am. J. Obstet. Gynecol. 174, 1354-1360 (1996).
61. Feikin DR, Thorsan P, Zywicki S et al. Association between colonization with group B streptococci during pregnancy and preterm delivery among Danish women. Am. J. Obstet. Gynecol. 184, 427-433 (2001).
62. De Azavedo JCS, McGavin M, Duncan C et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45, 3504-3508 (2001).
63. De Mouy D, Cavallo JD, Leclercq R et al. Antibiotic susceptibility and mechanisms of erythromycin resistance in clincal isolates of Streptococcus agalactiae: a French multicenter study. Antimicrob. Agents Chemother. 45, 2400-2402 (2001).
64. Ruess M, Mueller U, Sander A, Berner R. Antibiotic susceptibility pattern in Streptococcus agalactiae isolates in a German university hospital. Scand. J. Infect. Dis. 32, 623-626 (2000).
65. Murdoch DR, Rell LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob. Agents Chemother. 45, 3623-3624 (2001).
66. Fitoussi F, Loukil C, Gros I et al. Mechanism of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob. Agents Chemother. 45, 1889-1891 (2001).
67. LeClercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance element and their clinical implications. Clin. Infect. Dis. 34, 482-492 (2002).
68. Uh Y, Jang ICH, Hwang GY et al. Emerging erythromycin resistance among group B streptococci in Korea. Eur. J. Clin. Microbiol. Infect. Dis. 20, 52-54 (2001).
69. Diekema DJ, Andrews JI, Huynh H et al. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J. Clin. Microbiol. 41, 2659-2661 (2003).
70. Croak A, Abate G, Goodrum K, Modrzakowski M. Predominance of serotype V and frequency of erythromycin resistance in Streptococcus agalactiae in Ohio. Am. J. Obstet. Gynecol. 188, 1148-1150 (2003).
71. Poyart C, Jardy L, Quesne G, Berche P, Trieut-Cuot P. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob. Agents Chemother. 47, 794-797 (2003).
72. Kawamura Y, Fujiwara H, Mishima N et al. First Streptococcus agalactiae isolates highly resistant to quinolones with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47, 3605-3609 (2003).
73. Fernandez M, Rench MA, Albanyan EA et al. Failure of rifampin to eradicate group B streptococcal colonization in infants. Pediatr. Infect. Dis. J. 20, 371-376 (2001).
74. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcus Type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21, 3468-3472 (2003).
75. Schuchat A. Group B streptococcus. Lancet 353, 51-56 (1999).
76. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294, 753-756 (1976).
77. Lin FY, Phillips JB III, Azimi PH et al. Level of maternal antibody required to protect neonates against early onset disease caused by group B streptococcus Type Ia: a multicenter, seroepidemiology study. J. Infect. Dis. 184, 1022-1028 (2001).
78. Kasper DL, Paoletti LC, Wessels MR et al. Immune response to Type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98, 2308-2314 (1996).
79. Cheng Q, Carlson B, Pillai S et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect. Immun. 69, 2302-2308 (2001).
80. Shen X, Lagergard T, Yang Y et al. Preparation and preclinical evaluation of experimental group B Streptococcus Type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19, 850-861 (2001).
81. Larsson C, Holmgren J, Lindahl G, Bergquist C. Intranasal immunization of mice with group B streptococcal protein Rib and cholera toxin B subunit confers protection against lethal infection. Infect. Immun. 72, 1184-1187 (2004).
82. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B streptococcal disease on the incidence and ecology of early onset neonatal sepsis. Lancet Infect. Dis. 3, 201-213 (2003).
83. Schuchat A. Group B streptococcal disease: from trials and tribulations to triumph and trepidation. Clin. Infect. Dis. 33, 751-756 (2001).